Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer
NCT01255800
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
9
Enrollment
OTHER
Sponsor class
Conditions
Recurrent Head and Neck Cancer
Interventions
DRUG:
IPI-926 and Cetuximab
Sponsor
University of Colorado, Denver